Parkinson I S, Kealey T, Laker M F
Clin Chim Acta. 1985 Nov 15;152(3):335-45. doi: 10.1016/0009-8981(85)90109-3.
An enzyme/bioluminescent assay for the determination of oxalate in plasma is described in which NADH, a reaction product of the enzymic degradation of oxalate by oxalate decarboxylase and formate dehydrogenase, is determined using a commercially available bioluminescent system. In contrast to most previously documented methods, this sensitive and specific assay requires minimal sample preparation allowing oxalate concentrations to be determined within 2 h of sample collection. The limit of detection for plasma samples is 0.8 mumol/l. The recovery of oxalate added to plasma averaged 99%. The inter-batch coefficient of variation, calculated by analysis of a plasma sample from a uraemic patient (oxalate concentration = 45.8 mumol/l) on 8 occasions, over a period of 5 wk, was 3.2%. Plasma oxalate concentrations in 35 normal subjects ranged from less than 0.8-1.5 mumol/l, which is in excellent agreement with values obtained by in vivo isotope dilution studies. Plasma oxalate was found to be strikingly elevated in a group of uraemic patients maintained on regular haemodialysis.
本文描述了一种用于测定血浆中草酸盐的酶/生物发光测定法,其中草酸盐经草酸盐脱羧酶和甲酸脱氢酶酶促降解的反应产物NADH,使用市售生物发光系统进行测定。与大多数先前记录的方法不同,这种灵敏且特异的测定法所需的样品制备最少,能够在样品采集后2小时内测定草酸盐浓度。血浆样品的检测限为0.8μmol/L。添加到血浆中的草酸盐回收率平均为99%。通过在5周内8次分析一名尿毒症患者的血浆样品(草酸盐浓度 = 45.8μmol/L)计算得出的批间变异系数为3.2%。35名正常受试者的血浆草酸盐浓度范围为低于0.8 - 1.5μmol/L,这与体内同位素稀释研究获得的值非常一致。在一组接受定期血液透析的尿毒症患者中,发现血浆草酸盐显著升高。